Deborah D Stocken

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1452008/publications.pdf

Version: 2024-02-01

99 papers 14,041 citations

66343 42 h-index 93 g-index

102 all docs

 $\begin{array}{c} 102 \\ \\ \text{docs citations} \end{array}$

102 times ranked 14812 citing authors

#	Article	IF	CITATIONS
1	A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer. New England Journal of Medicine, 2004, 350, 1200-1210.	27.0	2,442
2	Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet, The, 2016, 387, 679-690.	13.7	1,397
3	Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection. JAMA - Journal of the American Medical Association, 2010, 304, 1073.	7.4	1,206
4	Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet, The, 2001, 358, 1576-1585.	13.7	1,019
5	Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncology, The, 2019, 20, 663-673.	10.7	773
6	Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2009, 27, 5513-5518.	1.6	708
7	Influence of Resection Margins on Survival for Patients With Pancreatic Cancer Treated by Adjuvant Chemoradiation and/or Chemotherapy in the ESPAC-1 Randomized Controlled Trial. Annals of Surgery, 2001, 234, 758-768.	4.2	560
8	Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clinical Gastroenterology and Hepatology, 2004, 2, 252-261.	4.4	543
9	Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunology, Immunotherapy, 2011, 60, 1419-1430.	4.2	506
10	Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. The Lancet Gastroenterology and Hepatology, 2017, 2, 565-575.	8.1	362
11	Optimal Duration and Timing of Adjuvant Chemotherapy After Definitive Surgery for Ductal Adenocarcinoma of the Pancreas: Ongoing Lessons From the ESPAC-3 Study. Journal of Clinical Oncology, 2014, 32, 504-512.	1.6	351
12	Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. British Journal of Cancer, 2005, 92, 1372-1381.	6.4	325
13	Guidelines for the Content of Statistical Analysis Plans in Clinical Trials. JAMA - Journal of the American Medical Association, 2017, 318, 2337.	7.4	290
14	Influence of Resection Margins and Treatment on Survival in Patients With Pancreatic Cancer. Archives of Surgery, 2008, 143, 75.	2.2	275
15	A Randomized Phase 2 Trial of Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer: Gemcitabine Alone Versus Gemcitabine Combined with Cisplatin. Annals of Surgical Oncology, 2007, 14, 2088-2096.	1.5	204
16	Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials. British Journal of Cancer, 2009, 100, 246-250.	6.4	193
17	Recovery of Hypoglycemia Awareness in Long-standing Type 1 Diabetes: A Multicenter 2 × 2 Factorial Randomized Controlled Trial Comparing Insulin Pump With Multiple Daily Injections and Continuous With Conventional Glucose Self-monitoring (HypoCOMPaSS). Diabetes Care, 2014, 37, 2114-2122.	8.6	183
18	Phase I Trial of Recombinant Modified Vaccinia Ankara Encoding Epstein–Barr Viral Tumor Antigens in Nasopharyngeal Carcinoma Patients. Cancer Research, 2013, 73, 1676-1688.	0.9	159

#	Article	IF	CITATIONS
19	Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study Journal of Clinical Oncology, 2017, 35, 4006-4006.	1.6	142
20	HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. Journal of Allergy and Clinical Immunology, 2019, 143, 2120-2130.	2.9	128
21	Modelling prognostic factors in advanced pancreatic cancer. British Journal of Cancer, 2008, 99, 883-893.	6.4	117
22	Adjuvant therapy in pancreatic cancer: historical and current perspectives. Annals of Oncology, 2003, 14, 675-692.	1.2	115
23	Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial. The Lancet Gastroenterology and Hepatology, 2018, 3, 25-36.	8.1	113
24	Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. The Lancet Gastroenterology and Hepatology, 2018, 3, 626-634.	8.1	103
25	A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. British Journal of Cancer, 2004, 91, 844-849.	6.4	98
26	Psoriasis treat to target: defining outcomes in psoriasis using data from a realâ€world, populationâ€based cohort study (the British Association of Dermatologists Biologics and) Tj ETQq0 0 0 rgBT /Ov	verl a 6k 10	Tf §® 457 Td
27	Symptom-based stratification of patients with primary Sjögren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. Lancet Rheumatology, The, 2019, 1, e85-e94.	3.9	76
28	Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. British Journal of Dermatology, 2019, 180, 1069-1076.	1.5	74
29	Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. British Journal of Cancer, 2004, 90, 2106-2111.	6.4	71
30	Elevated serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patients. British Journal of Cancer, 2007, 97, 971-977.	6.4	70
31	Influence of Surgical Resection and Post-Operative Complications on Survival following Adjuvant Treatment for Pancreatic Cancer in the ESPAC-1 Randomized Controlled Trial. Digestive Surgery, 2005, 22, 353-363.	1.2	68
32	Metaâ€analysis of fenestrated endovascular aneurysm repair <i>versus</i> open surgical repair of juxtarenal abdominal aortic aneurysms over the last 10 years. BJS Open, 2019, 3, 572-584.	1.7	67
33	Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study. Journal of Clinical Oncology, 2022, 40, 2048-2057.	1.6	65
34	Prevalence and socio-demographic correlates of cooking skills in UK adults: cross-sectional analysis of data from the UK National Diet and Nutrition Survey. International Journal of Behavioral Nutrition and Physical Activity, 2015, 12, 99.	4.6	63
35	Defining the Therapeutic Range for AdalimumabÂand Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study. Journal of Investigative Dermatology, 2019, 139, 115-123.	0.7	60
36	Sustained Reduction in Severe Hypoglycemia in Adults With Type 1 Diabetes Complicated by Impaired Awareness of Hypoglycemia: Two-Year Follow-up in the HypoCOMPaSS Randomized Clinical Trial. Diabetes Care, 2018, 41, 1600-1607.	8.6	58

#	Article	IF	CITATIONS
37	The Value of Source Data Verification in a Cancer Clinical Trial. PLoS ONE, 2012, 7, e51623.	2.5	58
38	The interâ€relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis. Alimentary Pharmacology and Therapeutics, 2016, 44, 1039-1050.	3.7	54
39	Preoperative Mitomycin, Ifosfamide, and Cisplatin Followed by Esophagectomy in Squamous Cell Carcinoma of the Esophagus: Pathologic Complete Response Induced by Chemotherapy Leads to Long-Term Survival. Journal of Clinical Oncology, 2003, 21, 4009-4015.	1.6	48
40	The Impact of Autoimmune Hepatitis and Its Treatment on Health Utility. Hepatology, 2018, 68, 1487-1497.	7.3	48
41	Intentional and Unintentional Medication Non-Adherence in Psoriasis: The Role of Patients' Medication Beliefs and Habit Strength. Journal of Investigative Dermatology, 2018, 138, 785-794.	0.7	48
42	A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis. PLoS ONE, 2017, 12, e0175717.	2.5	46
43	Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial. BMJ Open, 2013, 3, e003995.	1.9	41
44	Effect of Levothyroxine on Left Ventricular Ejection Fraction in Patients With Subclinical Hypothyroidism and Acute Myocardial Infarction. JAMA - Journal of the American Medical Association, 2020, 324, 249.	7.4	33
45	Longitudinal quality of life data can provide insights on the impact of adjuvant treatment for pancreatic cancer—Subset analysis of the ESPAC†data. International Journal of Cancer, 2009, 124, 2960-2965.	5.1	32
46	Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis. JAMA Dermatology, 2019, 155, 1235.	4.1	30
47	Cationic trypsinogen mutations and pancreatitis. Gastroenterology Clinics of North America, 2004, 33, 767-787.	2.2	29
48	Drooling Reduction Intervention randomised trial (DRI): comparing the efficacy and acceptability of hyoscine patches and glycopyrronium liquid on drooling in children with neurodisability. Archives of Disease in Childhood, 2018, 103, 371-376.	1.9	29
49	REpeated AutoLogous Infusions of STem cells In Cirrhosis (REALISTIC): a multicentre, phase II, open-label, randomised controlled trial of repeated autologous infusions of granulocyte colony-stimulating factor (GCSF) mobilised CD133+ bone marrow stem cells in patients with cirrhosis. A study protocol for a randomised controlled trial. BMI Open. 2015. 5. e007700-e007700.	1.9	28
50	Use of proton pump inhibitors to treat persistent throat symptoms: multicentre, double blind, randomised, placebo controlled trial. BMJ, The, 2021, 372, m4903.	6.0	28
51	Evaluation of the impact of the GRACE risk score on the management and outcome of patients hospitalised with non-ST elevation acute coronary syndrome in the UK: protocol of the UKGRIS cluster-randomised registry-based trial. BMJ Open, 2019, 9, e032165.	1.9	27
52	Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial. Lancet Rheumatology, The, 2021, 3, e337-e346.	3.9	24
53	Serum matrix metalloproteinase 9 and colorectal neoplasia: a community-based evaluation of a potential diagnostic test. British Journal of Cancer, 2012, 106, 1431-1438.	6.4	23
54	Enhanced NF-κB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis. Nature Communications, 2021, 12, 4741.	12.8	23

#	Article	IF	CITATIONS
55	An observer-blinded randomized controlled pilot trial comparing localized immersion psoralen-ultraviolet A with localized narrowband ultraviolet B for the treatment of palmar hand eczema. British Journal of Dermatology, 2018, 179, 63-71.	1.5	22
56	The NAtional randomised controlled Trial of Tonsillectomy IN Adults (NATTINA): a clinical and cost-effectiveness study: study protocol for a randomised control trial. Trials, 2015, 16, 263.	1.6	19
57	Gastrostomy versus nasogastric tube feeding for chemoradiation patients with head and neck cancer: the TUBE pilot RCT. Health Technology Assessment, 2018, 22, 1-144.	2.8	19
58	Cationic Trypsinogen Mutations and Pancreatitis. Clinics in Laboratory Medicine, 2005, 25, 39-59.	1.4	17
59	Targeting the rheumatoid arthritis synovial fibroblast via cyclin dependent kinase inhibition. Medicine (United States), 2020, 99, e20458.	1.0	16
60	The case for adjuvant chemotherapy in pancreatic cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2006, 20, 383-401.	2.4	15
61	Targeting Tropomyosin Receptor Kinase in Cutaneous CYLD Defective Tumors With Pegcantratinib. JAMA Dermatology, 2018, 154, 913.	4.1	14
62	Systematic review of radiological cervical foraminal grading systems. Neuroradiology, 2021, 63, 305-316.	2.2	13
63	Personalized Rate-Response Programming Improves Exercise Tolerance After 6 Months in People With Cardiac Implantable Electronic Devices and Heart Failure. Circulation, 2020, 141, 1693-1703.	1.6	12
64	Cost-effectiveness of cardiovascular imaging for stable coronary heart disease. Heart, 2021, 107, 381-388.	2.9	12
65	Early phase clinical trials extension to guidelines for the content of statistical analysis plans. BMJ, The, 2022, 376, e068177.	6.0	12
66	Surveillance versus ablation for incidentally diagnosed small renal tumours: the SURAB feasibility RCT. Health Technology Assessment, 2017, 21, 1-68.	2.8	11
67	A phase II irinotecan–cisplatin combination in advanced pancreatic cancer. British Journal of Cancer, 2003, 89, 1860-1864.	6.4	10
68	Diagnostic and mechanistic implications of serum free light chains, albumin and alpha-fetoprotein in hepatocellular carcinoma. British Journal of Cancer, 2014, 110, 2277-2282.	6.4	9
69	Doxycycline: a first-line treatment for bullous pemphigoid?. Lancet, The, 2017, 389, 1586-1588.	13.7	9
70	Antiplatelet therapy in the primary prevention of cardiovascular disease inÂpatients with chronic obstructive pulmonary disease: a randomised controlled proof-of-concept trial. ERJ Open Research, 2019, 5, 00110-2019.	2.6	9
71	A feasibility study incorporating a pilot randomised controlled trial of oral feeding plus pre-treatment gastrostomy tube versus oral feeding plus as-needed nasogastric tube feeding in patients undergoing chemoradiation for head and neck cancer (TUBE trial): study protocol. Pilot and Feasibility Studies, 2016, 2, 29.	1.2	8
72	TOPPITS: Trial Of Proton Pump Inhibitors in Throat Symptoms. Study protocol for a randomised controlled trial. Trials, 2016, 17, 175.	1.6	8

#	Article	IF	CITATIONS
73	Can mid-regional pro-adrenomedullin (MR-proADM) increase the prognostic accuracy of NEWS in predicting deterioration in patients admitted to hospital with mild to moderately severe illness? A prospective single-centre observational study. BMJ Open, 2018, 8, e020337.	1.9	7
74	Nasal Airway Obstruction Study (NAIROS): a phase III, open-label, mixed-methods, multicentre randomised controlled trial of septoplasty versus medical management of a septal deviation with nasal obstruction. Trials, 2020, 21, 179.	1.6	7
75	Establishing the added benefit of measuring MMP9 in FOB positive patients as a part of the Wolverhampton colorectal cancer screening programme. BMC Cancer, 2009, 9, 36.	2.6	6
76	Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial. British Journal of Cancer, 2013, 109, 2453-2461.	6.4	6
77	Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial. Trials, 2017, 18, 111.	1.6	6
78	Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study. Journal of Investigative Dermatology, 2020, 140, 2129-2137.	0.7	6
79	Antiplatelet therapy in the primary prevention of cardiovascular disease in patients with chronic obstructive pulmonary disease: protocol of a randomised controlled proof-of-concept trial (APPLE) Tj ETQq1 1	0.78 4.3 14 rş	gBT6/Overlock
80	Laryngeal dysplasia and narrow band imaging: Secondary analysis of published data supports the role in patient followâ€up. Clinical Otolaryngology, 2018, 43, 1439-1442.	1.2	5
81	Lansoprazole for persistent throat symptoms in secondary care: the TOPPITS RCT. Health Technology Assessment, 2021, 25, 1-118.	2.8	5
82	BIOlogical Factors that Limit sustAined Remission in rhEumatoid arthritis (the BIO-FLARE study): protocol for a non-randomised longitudinal cohort study. BMC Rheumatology, 2021, 5, 22.	1.6	4
83	The commercialization of clinical research: who pays the piper, calls the tune?. Family Practice, 2004, 21, 335-336.	1.9	3
84	Response to Comment on Little et al. Recovery of Hypoglycemia Awareness in Long-standing Type 1 Diabetes: A Multicenter 2 × 2 Factorial Randomized Controlled Trial Comparing Insulin Pump With Multiple Daily Injections and Continuous With Conventional Glucose Self-monitoring (HypoCOMPaSS). Diabetes Care 2014;37:2114–2122. Diabetes Care, 2014, 37, e272-e273.	8.6	2
85	Development of guidance for statistical analysis plans (SAPs) for clinical trials. Trials, 2015, 16, .	1.6	2
86	A pragmatic approach to the design and calibration of a Bayesian CRM dose finding trial. Trials, 2015, 16, .	1.6	2
87	Optimising pacemaker therapy and medical therapy in pacemaker patients for heart failure: protocol for the OPT-PACE randomised controlled trial. BMJ Open, 2019, 9, e028613.	1.9	2
88	Rationale and design of the LIBERATES trial: Protocol for a randomised controlled trial of flash glucose monitoring for optimisation of glycaemia in individuals with type 2 diabetes and recent myocardial infarction. Diabetes and Vascular Disease Research, 2020, 17, 147916412095793.	2.0	2
89	Innovations in Practice: A case control and follow-up study of †hard to reach' young people who suffered from multiple complex mental disorders. Child and Adolescent Mental Health, 2017, 22, 49-57.	3.5	1
90	Systematic review of interventions to increase the use of arteriovenous fistulae and grafts in incident haemodialysis patients. Journal of Vascular Access, 2021, , 112972982110069.	0.9	1

#	Article	IF	Citations
91	Folic acid supplementation in postmenopausal women with hot flushes: phase III randomised doubleâ€blind placeboâ€controlled trial. BJOG: an International Journal of Obstetrics and Gynaecology, 2021, 128, 2024-2033.	2.3	1
92	TRAFIC: statistical design and analysis plan for a pragmatic early phase $1/2$ Bayesian adaptive dose escalation trial in rheumatoid arthritis. Trials, 2021, 22, 433.	1.6	1
93	Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer. Annals of Surgical Oncology, 2008, 15, 2061-2061.	1.5	0
94	Orlistat for overweight subjects with nonalcoholic steatohepatitis. Hepatology, 2009, 50, 321-321.	7.3	0
95	Cholecystectomy in a Trial of Adjuvant Chemotherapy After Pancreatic Cancer Resection—Reply. JAMA - Journal of the American Medical Association, 2010, 304, 2590.	7.4	O
96	PERSONALISED RATE-RESPONSE PROGRAMMING IMPROVES LONG-TERM EXERCISE TOLERANCE IN PEOPLE WITH PACEMAKER DEVICES AND HEART FAILURE. Journal of the American College of Cardiology, 2020, 75, 318.	2.8	0
97	Non-invasive, vagus nerve stimulation to reduce ileus after colorectal surgery: protocol for a feasibility trial with nested mechanistic studies. BMJ Open, 2021, 11, e046313.	1.9	0
98	Progress by Collaboration: ESPAC Studies. , 2004, , 57-69.		0
99	Response by Gierula et al to Letter Regarding Article, "Personalized Rate-Response Programming Improves Exercise Tolerance After 6 Months in People With Cardiac Implantable Electronic Devices and Heart Failure: A Phase II Study― Circulation, 2020, 142, e319-e320.	1.6	O